Sublingual Immunotherapy (SLIT). Both contain the allergen extract from timothy grass (Phleum pratense). The objective of this analysis was to perform a pharmacoeconomic evaluation of SLIT with a grass allergy tablet compared to SCIT in both the Norwegian and Finnish markets. METHODS: A cost-minimisation approach was deemed appropriate for this evaluation, based on assessments of the alternative’s pharmacokinetic profiles, potential mechanisms of actions and an indirect comparison of results from clinical trials. SLIT was judged to provide at least comparable clinical outcomes to those of SCIT. Total costs from a societal perspective related to the therapies were calculated based on national data on resource use and unit costs. Estimates of resource use were based on guidelines, the literature and interviews with national clinical specialists. Resources included the quantities used of the chosen immunotherapy, the number of physician visits related to administration and follow up of the chosen therapy, patient travel and resources lost due to absence from work in connection with receiving the therapy. Unit costs were based on national tariffs and wage statistics. RESULTS: The expected savings in total cost of treatment with SLIT compared to SCIT are approximately 1160 € and 900 € in Norway and Finland respectively. Alternative scenarios and one-way sensitivity analyses indicate the robustness of the results. CONCLUSION: The result of this cost-minimisation analysis indicates that for patients with grass pollen induced rhinoconjunctivitis where immunotherapy is appropriate, SLIT with a grass allergy tablet is a cost-saving alternative to SCIT from a societal perspective, both in Norway and in Finland.

PAA8
COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN CZECH REPUBLIC—COST OF ILLNESS STUDY
Doležal T1, Skoupá J2
1Charles University, Prague, Czech Republic, 2Pharma Projects, Prague, Czech Republic
OBJECTIVES: Asthma patients with severe persistent disease (GINA Step 4) have the greatest medical need among the asthmatic population but also consume the highest economic costs. In our study we have selected severe persistent asthma patients who have not responded to high-dose antihistamatic drugs (inhaled and oral corticosteroids, long-LABA, antileukotrienes and theophylline). METHODS: In a retrospective setting we have collected direct and indirect costs for 51 patients (32 women and 19 men) over the period of one year with refractory asthma in four clinical centres during August to November 2006. RESULTS: The average time from diagnosis was 17.5 years. Two thirds of patients were fully disabled and in rest of patients working absence was more than 90 days per year. There was high occurrence of concomitant diagnoses—hypertension in 37%, osteoporosis in 33% and gastroopathy in 31% due to high doses of oral steroids. The mean length of hospitalization was 11.8 days per year in standard ward and 2.6 days in critical care. Emergency department was visited 8.1 times per year and outpatient departments more than 20 times during the analysed time period. Total direct medical costs were 4756 EUR/year. Expenditure for hospitalizations was 2320 EUR, outpatient care 374 EUR and emergency care 59 EUR. The cost of asthma medication was 1484 EUR and 226 EUR for other medication. Indirect costs (social and sickness benefits, productivity loss) were 7262 EUR per year. CONCLUSION: The annual total direct plus indirect costs of one patient with refractory severe persistent asthma were 12018 EUR. Based on this results there are unmet medical and economic needs in therapy of this subset of asthma patients in Czech Republic.

PAA9
RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES
Colice G1, Yu AP2, Ivanova J3, Hsieh M4, Birnbaum HG5, Lage MJ6, Brewster C7
1Washington Hospital Center, Washington, DC, USA, 2Analysis Group, Inc, Boston, MA, USA, 3HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 4Teva Neuroscience/Teva Specialty Pharmaceuticals, Kansas City, MO, USA
OBJECTIVES: Compare risk-adjusted costs and patient outcomes measured by hospitalizations and emergency room visits in mild persistent asthma patients initiating regular use of inhaled corticosteroids (ICS), ICS and long acting beta-agonists (LABA), or leukotriene modifiers (LM). METHODS: Study patients, selected from a privately insured claims database (1999–2005), had at least one asthma diagnosis; no diagnosis of COPD; mild persistent asthma as defined by the 2005 HEDIS, Leidy’s reliever and oral steroid methods; and the 2004 GINA guidelines; and initiated regular use of ICS, ICS + LABA or LM. Chi-squared tests were used for descriptive pairwise comparisons of patient outcomes. Generalized linear models with log link and gamma distribution adjusting for patient characteristics were used for comparisons of total and asthma-related direct costs in the 12-months after the first regular study controller use. RESULTS: The final sample included 319 patients with regular use of ICS, 414 patients with ICS + LABA, and 530 patients with LM. There were no significant differences in patient outcomes, as measured by hospitalizations and emergency room visits (all-cause as well as asthma-specific) among the three cohorts. Total risk-adjusted direct costs were significantly lower with ICS and LM compared with ICS + LABA (ICS: $4305, P = 0.0158 compared with ICS + LABA; ICS + LABA: $4997, P < 0.0857 compared with LM; LM: $4562) and not significantly different between ICS and LM. Asthma-related risk-adjusted direct costs were the lowest with ICS compared with both ICS + LABA and LM (ICS: $782, P < 0.01 compared with ICS + LABA, P < 0.01 compared with LM; ICS + LABA: $1126, P < 0.01 compared with LM; LM: $871). CONCLUSION: Regular ICS use in mild persistent asthma was associated with lower total direct costs compared with ICS + LABA and the lowest asthma-related direct costs compared with ICS + LABA or LM, without any corresponding difference in patient outcomes.

PAA10
ADULT ASTHMA: A COHORT ANALYSIS OF USE AND COST OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY LOCATION OF RESIDENCE OVER TWELVE MONTHS
O’Brien JA1, Duran PA, Caro JJ2
1United BioSource Corporation, Concord, MA, USA
OBJECTIVES: As asthma rates increase, questions about the relationship to residential location have been raised in many countries. Thus, inpatient and emergency department (ED) care for adult (age >= 17 years) asthmatics and related costs were examined by residential location for one year. METHODS: Using 2001–02 Massachusetts data, patients treated for asthma (ICD-9 principal diagnosis code: 493.00–493.92) were identified. An encounter profile was established for each patient starting with the first asthma-related stay/visit (index encounter) at any hospital or ED in 2001, and included all subsequent inpatient and ED care for asthma within twelve months. Using zip codes, patients
were classified by residential location (urban, suburban, rural). Massachusetts has 351 cities and towns; 10% urban, 19% rural, and 71% suburban. Hospital charges, adjusted by a 0.517 cost-to-charge ratio, medical inflation and geographic factors are reported in 2007 US$. RESULTS: The cohort (n=53,604) had 92,776 asthma-related encounters (65% ED visits) during the year. The proportion of ED visits for suburban patients was significantly (p<0.05) lower. On average, rural patients (2%) had 1.7 encounters (range: 1–11), 5.2 asthma-related care days and accrued $5280 per patient. Suburban patients (46%) averaged 1.6 encounters (range: 1–29), 5.5 care days and $9325 per patient. Urban patients (52%) had 1.8 encounters (range: 1–50), 5.9 care days and $8736 per patient, on average. Over the year, rural patients used 2768 inpatient days and 1582 ED hours accruing $4.9 million in asthma-related care costs. Suburban patients accrued 66,823 hospital days, 45,954 ED hours and $116.6 million. Urban patients used 74,339 hospital days and 46,196 ED hours in one year, accruing $116.1 million. CONCLUSION: Most patients were from urban locations; however those from suburban areas had a higher ratio of inpatient stays to ED visits, which contributed to the higher average asthma-related cost per suburban patient.

ECONOMIC EVALUATION OF SECOND-LINE THERAPIES IN ADULT PATIENTS WITH ASTHMA WHEN CONSIDERING COMPLIANCE—AN ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE

Pettersson B1, Soronz-Szabo T1, Ekman M2, Taylor SD1
1MSSD, Solentuna, Sweden. 2MSSD Hungary Kft, Budapest, Hungary.

OBJECTIVES: The objective of this study was to compare costs and effects of montelukast (MON) as add-on to inhaled corticosteroids (ICS) therapy for asthma, and approxi-

THE MONTREAL PROTOCOL: CONCERNS OVER THE FUTURE TREATMENT OF ASTHMA

Walters E1, Osborne M1, Ling C2, Johnson KI2
1Teva UK Ltd, Harlow, Essex, UK. 2Evidence Research Unit, Macclesfield, UK.

OBJECTIVES: It is estimated that over 4.6 million people suffer from asthma in England and Wales at an estimated annual cost to the National Health Service (NHS) of more than £889 million. Beclometasone dipropionate (BDP) is the current mainstay of inhaled corticosteroid (ICS) therapy for asthma, and approxi-

EXTENT OF UNCONTROLLED DISEASE AND ASSOCIATED MEDICAL COSTS IN SEVERE ASTHMA IN THE NETHERLANDS

Breekweldt-Postma NS1, Erkens JA1, Aalbers R2, van de Ven MJ3, Lammers JWJ4, Herings RMC1
1PHARMO Institute, Utrecht, The Netherlands. 2Martini Hospital, Groningen, The Netherlands. 3Rijnstate Hospital, Arnhem, The Netherlands. 4University Medical Center Utrecht, Utrecht, The Netherlands.

OBJECTIVES: Asthma is a major public health problem with considerable economic impact. The aim of this study was to assess the extent of uncontrolled disease and associated medical costs in severe asthma. METHODS: Data were obtained from the PHARMO Record Linkage System (PHARMO RLS) which includes drug dispensing and hospitalizations for 2 million subjects in The Netherlands. Severe asthma patients (12–49 years) were defined as those who had used long-acting beta-agonists and inhaled corticosteroids for over 200 days and short-acting beta agonists for at least 100 days in 2004. Uncontrolled asthma was defined as a hospitalization for asthma or use of multiple, short (<30 days) courses of oral corticosteroids. Reimbursed costs of asthma drugs and hospitalizations were calculated. A matched case-control analyses was performed to compare asthma treatment of cases (hospitalized for asthma or multiple courses of oral corticosteroids) and controls. RESULTS: A total of 4.7% of patients receiving at least 2 asthma preparations in the previous year had severe asthma. A total of 17.4% of these were defined as having uncontrolled asthma. Excess drug costs for uncontrolled asthma with hospitalization were €664 per patient per year and €282 per patient per year for patients without hospitalization. Including hospital admission costs, excess costs were over €10,000 per patient per year. Lack of control did not seem to be caused by under-treatment. CONCLUSION: Poor control of severe asthma leads to disproportionately increased direct costs compared to controlled severe asthma, especially when hospital admission is required. Hospitalized patients representing 2% of the patients with severe asthma are responsible for 23% of the total direct costs.

ALLERGY/ASTHMA—Health Care Use & Policy Studies

PAA13